FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1851453522> ?p ?o ?g. }

• W1851453522 endingPage "1169" @default.
• W1851453522 startingPage "1158" @default.
• W1851453522 abstract "Background Anti-tumour necrosis factor (anti-TNF) monoclonal antibodies have shown efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection, biosimilar versions of the originator products are being developed, such as the infliximab biosimilar CT-P13; however, some uncertainty exists regarding their pharmacology in IBD. Aim To review the literature on anti-TNF biosimilars focusing on pharmacokinetics, pharmacodynamic properties and comparative effectiveness, related to their use in IBD. Methods A PubMed literature search was performed using the following terms individually or in combination: ‘biosimilars,’ ‘CT-P13,’ ‘Crohn's disease,’ ‘inflammatory bowel disease,’ ‘ulcerative colitis,’ ‘anti-TNFα therapy,’ ‘infliximab,’ ‘adalimumab,’ ‘pharmacokinetics,’ ‘immunogenicity.’ Results Bioequivalence of CT-P13 and infliximab was shown in ankylosing spondylitis (AS) and therapeutic equivalence in rheumatoid arthritis (RA). Preliminary results of CT-P13 in IBD come from small post-marketing registries and case series with a relatively short-term follow-up period and suggest comparable efficacy and safety to infliximab. Inter- and intra-individual differences in exposure and response are well known for the original molecules but dosing regimens and concomitant medications are different for RA compared to IBD, limiting the ability to translate some of the pharmacology data in RA to IBD. Uncertainty exists about cross-reactivity of anti-drug antibodies and whether similar exposure–response relationships will be observed for biosimilars and efficacy thresholds for therapeutic drug monitoring can be used interchangeably. Conclusions It is likely that biosimilars will be widely used for the treatment of IBD due to their cost savings and comparable efficacy. Nevertheless, robust post-marketing studies and pharmacovigilance are warranted in the coming years." @default.
• W1851453522 created "2016-06-24" @default.
• W1851453522 creator A5008693009 @default.
• W1851453522 creator A5019474609 @default.
• W1851453522 creator A5028386079 @default.
• W1851453522 creator A5048464948 @default.
• W1851453522 creator A5052278532 @default.
• W1851453522 creator A5052596220 @default.
• W1851453522 creator A5067530802 @default.
• W1851453522 creator A5069015142 @default.
• W1851453522 creator A5069469957 @default.
• W1851453522 creator A5082317019 @default.
• W1851453522 creator A5088443246 @default.
• W1851453522 date "2015-09-13" @default.
• W1851453522 modified "2023-10-18" @default.
• W1851453522 title "Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases" @default.
• W1851453522 cites W1085005885 @default.
• W1851453522 cites W1560551965 @default.
• W1851453522 cites W1654227300 @default.
• W1851453522 cites W1827882046 @default.
• W1851453522 cites W1965347749 @default.
• W1851453522 cites W1971219506 @default.
• W1851453522 cites W1971471395 @default.
• W1851453522 cites W1977913171 @default.
• W1851453522 cites W1980282196 @default.
• W1851453522 cites W1985701112 @default.
• W1851453522 cites W1985763670 @default.
• W1851453522 cites W1995734769 @default.
• W1851453522 cites W1996472975 @default.
• W1851453522 cites W2000500639 @default.
• W1851453522 cites W2003835888 @default.
• W1851453522 cites W2008531871 @default.
• W1851453522 cites W2011931673 @default.
• W1851453522 cites W2020859458 @default.
• W1851453522 cites W2022888597 @default.
• W1851453522 cites W2023193839 @default.
• W1851453522 cites W2023749561 @default.
• W1851453522 cites W2024155192 @default.
• W1851453522 cites W2025398922 @default.
• W1851453522 cites W2033039826 @default.
• W1851453522 cites W2036508874 @default.
• W1851453522 cites W2039232895 @default.
• W1851453522 cites W2041167828 @default.
• W1851453522 cites W2044160586 @default.
• W1851453522 cites W2045088225 @default.
• W1851453522 cites W2047363112 @default.
• W1851453522 cites W2053816562 @default.
• W1851453522 cites W2058586537 @default.
• W1851453522 cites W2071427170 @default.
• W1851453522 cites W2073559164 @default.
• W1851453522 cites W2076523377 @default.
• W1851453522 cites W2086721113 @default.
• W1851453522 cites W2094573863 @default.
• W1851453522 cites W2102907120 @default.
• W1851453522 cites W2113182448 @default.
• W1851453522 cites W2114127266 @default.
• W1851453522 cites W2121050884 @default.
• W1851453522 cites W2134036184 @default.
• W1851453522 cites W2140163728 @default.
• W1851453522 cites W2148487286 @default.
• W1851453522 cites W2149858688 @default.
• W1851453522 cites W2162768160 @default.
• W1851453522 cites W2172257129 @default.
• W1851453522 cites W4232260140 @default.
• W1851453522 cites W4232842991 @default.
• W1851453522 cites W4234279240 @default.
• W1851453522 cites W4234614328 @default.
• W1851453522 cites W4240919941 @default.
• W1851453522 cites W4245560145 @default.
• W1851453522 cites W4246027888 @default.
• W1851453522 cites W4250739352 @default.
• W1851453522 cites W4253139946 @default.
• W1851453522 doi "https://doi.org/10.1111/apt.13402" @default.
• W1851453522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26365281" @default.
• W1851453522 hasPublicationYear "2015" @default.
• W1851453522 type Work @default.
• W1851453522 sameAs 1851453522 @default.
• W1851453522 citedByCount "47" @default.
• W1851453522 countsByYear W18514535222016 @default.
• W1851453522 countsByYear W18514535222017 @default.
• W1851453522 countsByYear W18514535222018 @default.
• W1851453522 countsByYear W18514535222019 @default.
• W1851453522 countsByYear W18514535222020 @default.
• W1851453522 countsByYear W18514535222021 @default.
• W1851453522 countsByYear W18514535222022 @default.
• W1851453522 countsByYear W18514535222023 @default.
• W1851453522 crossrefType "journal-article" @default.
• W1851453522 hasAuthorship W1851453522A5008693009 @default.
• W1851453522 hasAuthorship W1851453522A5019474609 @default.
• W1851453522 hasAuthorship W1851453522A5028386079 @default.
• W1851453522 hasAuthorship W1851453522A5048464948 @default.
• W1851453522 hasAuthorship W1851453522A5052278532 @default.
• W1851453522 hasAuthorship W1851453522A5052596220 @default.
• W1851453522 hasAuthorship W1851453522A5067530802 @default.
• W1851453522 hasAuthorship W1851453522A5069015142 @default.
• W1851453522 hasAuthorship W1851453522A5069469957 @default.
• W1851453522 hasAuthorship W1851453522A5082317019 @default.
• W1851453522 hasAuthorship W1851453522A5088443246 @default.

• next